KANTOFF AARON 4

What Happened

• Aaron Kantoff, a director of Avalo Therapeutics (AVTX), had 3,166 restricted stock units (RSUs) vest and convert into 3,166 shares of common stock on March 28, 2026. The filing records an acquisition of 3,166 shares via conversion and a simultaneous disposition of 3,166 shares at $0.00.
• Footnote in the filing clarifies RSUs convert one-for-one into common stock. No cash consideration or sale proceeds are reported for the disposed shares.

Key Details

• Transaction date: 2026-03-28; Form 4 filed: 2026-03-31.
• Acquired: 3,166 shares (conversion of RSUs). Disposed: 3,166 shares at $0.00 (reported as a derivative disposal).
• Footnote: The original grant (Aug 13, 2024) was 9,500 RSUs vesting in three equal tranches on 3/28/2025, 3/28/2026 and 3/28/2027, subject to continued service.
• Shares owned after the transaction: not specified in the provided filing excerpt.
• The filing shows conversion and an immediate disposition of the same number of shares; filings often show this pattern when shares are surrendered/withheld to satisfy taxes, but the form does not explicitly state the reason.

Context

• This is a conversion of RSUs (derivative-to-common conversion), not an open-market buy or sale for cash. Such conversions are routine when RSUs vest; any simultaneous surrender of shares often reflects tax withholding or similar administrative actions rather than a market sale.
• Because the reporting shows equal acquisition and disposition counts, there is no reported cash proceeds and no net increase in shares from this specific transaction.